Cizzle Biotechnology

Cizzle Biotechnology is on a mission to transform lung cancer survival rates through early detection. The company's core innovation is a simple blood test that detects the CIZ1B biomarker with high sensitivity, offering a more accessible and affordable alternative to current CT scan-based screening. Publicly listed and backed by research from the University of York, Cizzle is progressing through clinical validation and building partnerships to commercialize its life-saving diagnostic technology globally.

Proprietary immunoassay platform for detecting the CIZ1B biomarker, a lung cancer-specific variant, in blood samples to enable early, non-invasive diagnosis.

Total raised: $8M

Competes against standard low-dose CT scans and other liquid biopsy companies developing multi-cancer or lung-cancer specific early detection tests (e.g., Grail, Guardant Health). Cizzle differentiates through its focus on a single, proprietary biomarker (CIZ1B) for lung cancer, aiming for high sensitivity, simplicity, and lower cost to improve accessibility and integration into existing screening pathways.